Replies to post #63695 on Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Good point, the stock was over $8 a year ago. If DOs removal, the interim CEO, delay in NEO was Amgens direction setting up for a sale, the uncertainty has killed the stock so I agree the valuation sale premium should be based in the stock when it was in the $8-$9 range a year ago. Lombardo has an M&A background so hopefully he gets us a sale valuation closer to $1b than $500m.